Allergan has successfully completed its previously announced $2.1 billion acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of prescription products for the medical aesthetics market.

With the acquisition, Allergan gains Kybella (deoxycholic acid) injection, the first FDA approved non-surgical injection for improvement in the appearance of moderate to severe submental fullness, commonly referred to as double-chin, in adults. The drug, which was approved earlier this year, is administered by a trained physician who injects the product under a patient’s chin to destroy fat cells, improving the appearance of the patient’s chin area. Up to six treatments may be administered per patient no less than one month apart, and each in-office treatment session lasts approximately twenty minutes.

The acquisition also adds Kythera’s development product setipiprant (KYTH-105), a compound for the prevention of androgenetic alopecia (AGA), or male pattern hair loss, as well as additional early-stage development candidates. Kythera submitted an investigational new drug application to the US Food and Drug Administration (FDA) for setipiprant for the treatment of AGA. Allergan plans to conduct a human proof-of-concept study to evaluate the efficacy and safety of setipiprant in male subjects with AGA.

Source: Allergan